Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

ClinicalTrials.gov ID: NCT02906917

Public ClinicalTrials.gov record NCT02906917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.

Study identification

NCT ID
NCT02906917
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
532 participants

Conditions and interventions

Interventions

  • Insulin aspart Drug
  • Insulin degludec/insulin aspart Drug
  • Insulin glargine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 19, 2016
Primary completion
Aug 30, 2017
Completion
Dec 23, 2017
Last update posted
Nov 12, 2019

2016 – 2017

United States locations

U.S. sites
30
U.S. states
13
U.S. cities
29
Facility City State ZIP Site status
Novo Nordisk Investigational Site Glendale Arizona 85306-4652
Novo Nordisk Investigational Site Phoenix Arizona 85050
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site Fresno California 93720
Novo Nordisk Investigational Site La Jolla California 92037
Novo Nordisk Investigational Site Northridge California 91325
Novo Nordisk Investigational Site Danbury Connecticut 06810
Novo Nordisk Investigational Site Fort Lauderdale Florida 33312
Novo Nordisk Investigational Site Fort Lauderdale Florida 33316
Novo Nordisk Investigational Site Jacksonville Florida 32205
Novo Nordisk Investigational Site Kissimmee Florida 34744
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Louisville Kentucky 40213
Novo Nordisk Investigational Site Chesterfield Missouri 63017
Novo Nordisk Investigational Site New York New York 10029
Novo Nordisk Investigational Site Westfield New York 14787
Novo Nordisk Investigational Site Wilmington North Carolina 28401
Novo Nordisk Investigational Site Franklin Ohio 45005
Novo Nordisk Investigational Site Bartlett Tennessee 38133
Novo Nordisk Investigational Site Chattanooga Tennessee 37411
Novo Nordisk Investigational Site Kingsport Tennessee 37660
Novo Nordisk Investigational Site Knoxville Tennessee 37938
Novo Nordisk Investigational Site Nashville Tennessee 37228
Novo Nordisk Investigational Site Austin Texas 78758
Novo Nordisk Investigational Site Dallas Texas 75390-9302
Novo Nordisk Investigational Site San Antonio Texas 78230
Novo Nordisk Investigational Site Chesapeake Virginia 23321
Novo Nordisk Investigational Site Midlothian Virginia 23114
Novo Nordisk Investigational Site Winchester Virginia 22601-3834

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02906917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2019 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02906917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →